drugset / Trial / NCT01232049

Drug Interaction and Safety Between Pitavastatin and Valsartan (CWP-PTV-101)

NCT01232049

Phase 1 Completed 24 enrolled Asan Medical Center JW Pharmaceutical · collab
RandomizedCrossoverOpen-labelSupportive care

Summary

This study is designed to evaluate a pharmacokinetic drug interaction and safety between Pitavastatin and Valsartan in healthy male subjects

Timeline

Start
2010-10
Primary completion
2011-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Pitavastatin Small molecule 4 mg Oral
Subject Valsartan Small molecule 320 mg Oral

Indications

No indication recorded.